

Evaluation of Hepcidin Level in COVID-19 Patients Admitted to the Intensive Care Unit

Marco Ciotti ^{1,*}, Marzia Nuccetelli ², Massimo Pieri ^{2,3}, Carlo Maria Petrangeli ⁴, Alfredo Giovannelli ², Terenzio Cosio ^{3,7}, Luigi Rosa ⁵, Piera Valenti ⁵, Francesca Leonardis ⁴, Jacopo Maria Legramante ⁶, Sergio Bernardini ^{2,3,7}, Elena Campione ^{8,†}, Marilena Minieri ^{2 and 3,†,*}

- ¹ Virology Unit, Polyclinic Tor Vergata, Viale Oxford 81, 00133 Rome, Italy; marco.ciotti@ptvonline.it
- ² Department of Laboratory Medicine, Polyclinic Tor Vergata, Viale Oxford 81, 00133 Rome, Italy; marzi-anuccetelli@yahoo.com; massimo.pieri@uniroma2.it; alfredo.giovannelli@gmail.com; bernards@uniroma2.it; marilenami@gmail.com
- ³ Department of Experimental Medicine, University of Tor Vergata, Rome, Italy
- ⁴ Intensive Care Unit, Polyclinic Tor Vergata, Oxford 81, 00133 Rome, Italy; carlo.petrangeli@ptvonline.it; francesca.leonardis@ptvonline.it
- ⁵ Department of Public Health and Infectious Diseases, University of Rome “La Sapienza”, Rome, Italy; luigi.rosa@uniroma1.it; piera.valenti@uniroma1.it
- ⁶ Emergency Medicine, Polyclinic Tor Vergata, Viale Oxford 81, 00133 Rome, Italy; jacopo.legramante@ptvonline.it
- ⁷ Emerging Technologies Division (ETD) of the International Federation Clinical Chemistry and Laboratory Medicine (IFCC), Milan, Italy
- ⁸ Dermatology Unit, Department of Systems Medicine, Polyclinic Tor Vergata, 00133 Rome, Italy; terenzio-cosio@gmail.com; campioneelena@hotmail.com
- † These authors equally contributed.
- * Correspondence: marco.ciotti@ptvonline.it

Citation: Ciotti, M.; Nuccetelli, M.; Pieri, M.; Petrangeli, C.M.; Giovannelli, A.; Cosio, T.; Rosa, L.; Valenti, P.; Leonardis, F.; Legramante, J.M.; et al. **Evaluation of Hepcidin Level in COVID-19 Patients Admitted to the Intensive Care Unit.** *Diagnostics* **2022**, *12*, x. <https://doi.org/10.3390/xxxxx>

Academic Editor(s):

Received: date

Accepted: date

Published: date

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Coronavirus disease 2019 (COVID-19) presents a clinical spectrum that ranges from a mild condition to critical illness. Patients with critical illness present respiratory failure, septic shock and/or multi-organ failure induced by the so called “cytokines storm”. Inflammatory cytokines affect iron metabolism mainly inducing the synthesis of hepcidin, a hormone peptide not routinely measured. High levels of hepcidin have been associated with the severity of COVID-19. The aim of this study was to analyze retrospectively the levels of hepcidin in a group of COVID-19 patients admitted to the intensive care unit (ICU) of the Policlinico Tor Vergata of Rome, Italy. Thirty-eight patients from November 2020 to May 2021 were enrolled in the study. Based on the clinical outcome, the patients were assigned to two groups: survivors and non-survivors. Moreover, a series of routine laboratory parameters were monitored during the stay of the patients in the ICU and their levels correlated to the outcome. Statistical differences in the level of hepcidin, D-dimer, IL-6, LDH, NLR, neutrophils level, CRP, and TNF- α were observed between the groups. In particular, hepcidin values showed significantly different median concentrations (88 ng/ml vs 146 ng/ml) between survivors and non-survivors. In addition, ROC curves analysis revealed good sensitivity and specificity values of 74% and 76%, respectively, at a cut-off of 127 (ng/ml), indicating hepcidin as a good biomarker in predicting the severity and mortality of COVID-19 in ICU patients.

Keywords: COVID-19; Hepcidin; ICU

1. Introduction

Coronavirus disease 2019 (COVID-19) caused by the recently uncovered human coronavirus SARS-CoV-2 [1] presents a clinical picture that ranges from a mild condition to critical illness [2]. Patients with critical illness present respiratory failure, septic shock

and/or multi-organ failure induced by the so defined “cytokines storm” [3]. This exaggerated inflammatory response is characterized by increased level of several cytokines including IL-2, IL-6, IL-7 and interferon- γ inducible protein-10, macrophage inflammatory protein 1- α , tumor necrosis factor- α (TNF- α), monocyte chemoattractant protein 1, and granulocyte colony stimulating factor [4]. Inflammatory cytokines affect iron metabolism mainly inducing the synthesis of hepcidin [5], a 25 amino acid peptide synthesized primarily in liver cells, which is the principal regulator of iron absorption and its distribution to tissues. Hepcidin modulates cellular iron export to plasma and extracellular fluid through ferroportin, which acts as hepcidin receptor and cellular iron exporter in vertebrates. The levels of hepcidin are homeostatically regulated by iron and erythropoietic activity. An excess of iron stimulates the production of hepcidin that in turn inhibits the absorption of iron from the intestine. On the contrary, hepcidin is suppressed in iron deficiency allowing dietary iron absorption and replenishment of iron storage [6, 7]. In inflammation and infection, we observe an increase in the hepcidin level likely linked to the host defense mechanism to subtract iron to the infecting microorganisms [8]. Hepcidin sequesters iron mainly through macrophages [9]. This phenomenon is well known in bacterial infections, while its role in viral infections is unclear. Iron metabolism has implications on the function of the immune system. Lymphocytes are primed by contact with the antigen presenting cells, and they need iron to mount a robust and effective cellular and humoral response.

Despite the fundamental role of hepcidin in the regulation of iron metabolism, hepcidin is not routinely measured in clinic laboratory. Preliminary studies showed that high levels of hepcidin in COVID-19 patients are associated with the severity of the disease [5, 10]. Similarly, low levels of serum iron correlated with the severity and mortality of COVID-19 [11] and severe hypoxemia in intensive care unit (ICU) patients [12].

Given this background, the study aimed at analyzing retrospectively the levels of hepcidin in a group of COVID-19 patients admitted to the ICU of the Policlinico Tor Vergata of Rome, Italy. The levels of hepcidin were correlated to the outcome of the disease.

2. Materials and Methods

2.1. Study Group

Thirty-eight patients admitted to ICU from November 2020 to May 2021 because of severe pneumonia caused by SARS-CoV-2 were enrolled in the study. Based on the clinical outcome, the patients were assigned to two groups: survivors and non-survivors. The median age in the survivors group was 65.5 years old, while in the non-survivors was 73.5 years old. Eighteen patients belonged to the survivors group (13 males; 5 females) and 20 to the non-survivors group (10 males; 10 females). A series of laboratory parameters were monitored during the stay of the patients in the ICU and their levels correlated to the clinical outcome.

The study was approved by the local Ethical Committee of the Azienda Ospedaliera Policlinico Tor Vergata, under the protocol number 42.20/2020.

2.2. Measurement of Hepcidin Level

Hepcidin level was measured using the “Intrinsic Hepcidin IDx™ ELISA kit” (Intrinsic Lifesciences, San Diego, CA, USA), which is a competitive immunoenzymatic assay based on a monoclonal antibody (mAb) with high affinity to the N-terminus of hepcidin-25. This antibody also binds low abundance, N-terminus isomers of hepcidin-25 but with lower affinities. The assay was used for quantitative measurement of hepcidin in human serum. Hepcidin-25 in the test specimen competes with a biologically active biotinylated human hepcidin-25 tracer for the binding to high affinity anti-hepcidin-25 N-terminal specific mAbs coated on the plate. Briefly, standards (ranging from 0 to 1000 ng/ml), controls

and samples were incubated with biotinylated hepcidin-25 tracer for 60 min. After washing, a conjugate solution labeled with horseradish peroxidase (HRP) was dispensed into each well for 30 min. Finally, a chromogenic solution containing HRP substrate (tetramethylbenzidine; TMB) was added for 15 min, and the reaction was then stopped by an acidic solution. The absorbances were read spectrophotometrically at 450 nm on a plate reader (DAS srl, Rome, Italy). Optical densities are inversely proportional to hepcidin-25 concentration in the samples. This test is CE approved.

2.3. Measurement of Other Laboratory Parameters

Hematological and biochemical parameters were measured on blood, serum, and plasma samples collected at the ICU. White blood cells (WBCs), eosinophils, lymphocytes, neutrophils count, hemoglobin and platelets were measured by using an automated hematological analyzer (Dasit Sysmex, Milan, Italy). The neutrophil-to-lymphocyte ratio (NLR) and Lymphocyte-Neutrophil ratio (LNR) was also determined. Serum levels of high-sensitivity C-reactive protein (hsCRP; reference range 0–5 mg/L) were measured by using an immunoturbidimetric method (Abbott Diagnostics, Milan, Italy). Serum levels of Tumour Necrosis Factor alpha (TNF- α) (reference range: 0–12.4 pg/mL) were measured using an enzyme-linked immunosorbent assay (ELISA) technique (DRG, International Instruments GmbH, Marburg, Germany). Serum levels of Interleukin-6 (IL-6) (reference range: 0–50 pg/ mL) were measured using the chemiluminescence method (IMMULITE 2000 instrument, Siemens, Milan, Italy). Serum levels of ferritin (reference range: 21.81–274.66 ng/mL) were measured using the chemiluminescence method and lactate dehydrogenase (LDH) (reference range: 125.00–220.00 U/L) using an enzymatic colorimetric method (Alinity Instrument, Abbott, Milan, Italy). Plasma fibrinogen concentrations (reference range: 200–400 mg/dL) and plasma D-dimer levels (reference range: 0–500 ng/mL) were measured by ACL-TOP 500 instrumentation (Werfen, Milan, Italy).

2.4. Statistical Analysis

Descriptive statistics were calculated. Both the histogram and the Kolmogorov-Smirnov test of normality (p value < 0.05) were used to check whether the data were normally distributed. In the presence of a normal distribution of data, parametric tests were used such as analysis of variance with Bonferroni post hoc test in the case of more than two variables, or t test in the case of two variables. Otherwise, non-parametric tests, such as Kruskal-Wallis test (variables with more than two categories) and Mann-Whitney U test (variables with two categories), were used to test differences between different groups. A p value of less than 0.05 was considered statistically significant in all statistical analyses. ROC curve analysis was performed to assess sensitivity and specificity of biochemical parameters in survivors *vs* non-survivors COVID-19 patients.

All statistical analyses were performed using MedCalc Version 18.2.18 (MedCalc Software Ltd, Ostend, Belgium).

3. Results

The study included 18 patients in the survivors group (13 males and 5 females) and 20 patients in the non-survivors group (10 males and 10 females). They were homogeneous regarding age; median age 65.5 years (I.R. 58–74) in the survivors group, and 73.5 years (I.R. 66.5–79.5) in the non-survivors, ($p > 0.05$). Several clinical biochemical tests were evaluated and the results are shown in Table 1.

Table 1. Statistical analysis of laboratory parameters. For each study group are indicated: minimum, maximum, median and 95% confidence interval. A p-value higher than 0.05 (> 0.05) is not statistically significant.

	Survivors				non-Survivors				p-value
	Min	Max	Median	95% CI	Min	Max	Median	95% CI	
Aspartate Aminotransferase (U/L)	15	59	29	21.06 to 40.08	12	1876	31	23.34 to 53.65	0.455
D-dimer (ng/mL)	80	4507	1062.5	485.9 to 1770.9	581	35873	2223	1156.41 to 3802.27	0.014
Eosinophils (thousand/ μ L)	0	1.15	0.0450	0.020 to 0.10	0	0.81	0.01	0.0 to 0.11	0.86
Hepcidin (ng/mL)	10.2	198.1	88	33.03 to 126.69	13.08	971.44	144.96	111.67 to 245.59	0.005
Ferritin (ng/ml)	198	1315	596.5	332.27 to 763.80	434.01	11853	1335	487.57 to 4555.79	0.17
Fibrinogen (mg/dl)	95	919	450	367.38 to 556.62	36	1144	508	392.0 to 611.55	0.438
Hemoglobin (ng/dL)	8	13.9	10.95	9.61 to 12.02	7.6	15.3	9.7	8.7 to 11.03	0.52
Interleukin-6 (pg/ml)	5	84.3	22	7.48 to 73.10	13	517	124	19.48 to 392.95	0.032
Lactate Dehydrogenase (U/L)	184	974	231	200.47 to 329.44	185	737	400	292.48 to 518.44	0.003
Leucocyte (thousand/ μ L)	0.29	13	3.21	0.812 to 6.603	0.26	49	1.01	0.547 to 9.651	0.9895
Lymphocytes (thousand/ μ L)	0.27	21.7	0.915	0.60 to 1.39	0.26	2.59	0.58	0.56 to 1.047	0.168
Lipase (U/L)	9	137	30	24.26 to 44.42	7	328	28	23.0 to 59.49	0.849
Neutrophils (thousand/ μ L)	2.83	21.69	5.045	4.52 to 7.19	0.41	47.88	12.12	9.86 to 13.80	0.0001
Neutrophil-Lymphocyte ratio (NLR)	0.204	36.15	7.311	4.01 to 9.87	6.198	68.345	20.5	16.56 to 28.13	0.0001
C-reactive protein (mg/L)	2.3	228.8	33.9	7.34 to 157.62	11.2	337.6	148.35	66.93 to 236.06	0.015
Platelets (thousand/ μ L)	59	485	225.5	172.31 to 304.24	55	439	178	144.48 to 242.20	0.27
Tumour Necrosis Factor- α (pg/ml)	0.97	24	9	1.448 to 19.31	2	75	17	11.89 to 22.02	0.0438

Statistically significant differences in the level of hepcidin, D-dimer, IL-6, LDH, neutrophils count, NLR, CRP and TNF- α (Mann-Whitney U test; $p < 0.05$) were observed between the survivors and non-survivors groups (Table 1 and Fig. 1); no statistically significant differences were observed between the two groups of patients for AST/GOT, leucocyte count, eosinophils count, ferritin, fibrinogen, hemoglobin, lymphocytes count, lipase, and platelets, Table 1. In particular, hepcidin values show significantly different median concentrations (88 ng/ml vs 146 ng/ml) between the survivors and non survivors group, respectively ($p < 0.005$). In Figure 1 are reported the median values with the 25th and 75th percentile and the individual data obtained from the patients.

141
142
143

144
145
146
147
148
149
150
151
152
153




Figure 1. Serum levels of laboratory parameters significantly different in non-survivors and survivors groups (* $p < 0.05$, ** $p < 0.01$ Mann-Whitney U test).

Finally, ROC curve analyses were performed on the laboratory parameters with significant differences. Data obtained are reported in Table 2. LDH and IL-6 showed the best sensitivity (95%) and specificity (100%) values, respectively. Results for all other routine parameters are in line with the current literature. Hepcidin showed good sensitivity and specificity values of 74% and 76% respectively, at a cut-off of 127 (ng / ml) with an A.U.C. of 0.813 (Figure 2). Thus, a value of hepcidin lower than 127 (ng / ml) at hospital admission is suggestive of a favorable prognosis, also used alongside other biomarkers.

Table 2. ROC curve analysis of laboratory parameters in non-survivors and survivors groups. Sensitivity, specificity, cut-off, area under curve (AUC) and 95% Confidence interval are reported.

n= 38; 18 survived, 20 died	D-dimer (ng/mL)	Hepcidin (ng/mL)	IL-6 (pg/mL)	Lactate Dehydrogenase (U/L)	Neutrophils (thousand/ μ L)	Neutrophil Lymphocyte ratio (NLR)	C-reactive protein (mg/L)	Tumour Necrosis Factor- α (pg/ml)
Sensitivity (%)	52	74	75	95	91	82	82	80
Specificity (%)	83	76	100	56	78	83	61	43
Cut-off	>1981	>127	>84	>234	>7.62	>12.75	>41.5	>17.35
Area under the ROC curve (AUC); 95% Confidence interval	0.726; 0.564 to 0.853	0.813; 0.659 to 0.919	0.830; 0.553 to 0.970	0.779; 0.617 to 0.895	0.853; 0.707 to 0.944	0.850; 0.704 to 0.942	0.748; 0.573 to 0.879	0.557; 0.302 to 0.792




Figure 2. ROC curve analysis of hepcidin in non-survivors and survivors groups.

4. Discussion

COVID-19 since its first appearance at the end of 2019 spread rapidly thought the world causing millions of deaths [13]. Although most of the patients present mild symptoms and have a good prognosis, some patients develop a more severe clinical condition including severe pneumonia, acute respiratory distress or multiorgan failure with death [14]. In these critically ill patients, a massive inflammatory response with the release of numerous cytokines, known as “cytokine storm”, can be observed [15]. This inflammatory response alters a series of hematological and biochemical parameters.

Recent studies investigated the potential role of hepcidin (an important regulator of iron metabolism) as predictor of disease severity and mortality in COVID-19 patients [5, 10, 33]. Indeed, elevated serum levels of hepcidin were found in patients with severe disease or unfavorable outcome.

On this regard, in this study, we evaluated the routine hematological and biochemical profile as well as the hepcidin level, in a group of COVID-19 patients with severe pneumonia admitted to the ICU

Our analyses showed that there are statistically significant differences in the level of some parameters between survivors and non-survivors. In particular, higher levels of D-

dimer, IL-6, LDH, NLR, CRP and TNF- α were observed in the non-survivors compared to the survivors.

Elevated levels of D-dimer (a biomarker used to detect thrombosis) are linked to poor prognosis and need of ICU care in COVID-19 patients [16, 17]. A recent meta-analysis [18] reported that patients who died had a higher level of D-dimer compared to those who survived, leading to conclusions in agreement with our results.

LDH is a recognized biomarker of COVID-19 severity and mortality [19]. This observation was confirmed by a recent meta-analysis that also denoted how LDH is much higher in ICU *vs* non-ICU patients and in non-survival patients *vs* survival patients. Thus, it can be used as predictor of survival [20]. The importance of the prognostic value of LDH level in COVID-19 patients has been reconfirmed by a large retrospective study published at the beginning of 2022 [21]. Univariate regression analysis showed that patients with elevated LDH level had a higher risk of in-hospital death than those with normal or decreased level of LDH. In addition, the Kaplan-Meier curves showed that elevated LDH was associated with in-hospital death [21]. In our study, the higher level of LDH in non-survivors group *vs* survivors supports this last consideration.

Numerous scientific articles reported on the association of IL-6 and TNF- α with the severity and mortality of COVID-19 [22-26]. Elevated levels of these two biomarkers significantly increase the risk of disease severity and mortality as it has been recently reviewed in a study which included a large sample size. The non-survivors patients presented a marked difference in the level of IL-6 compared to the survivors [27]. A similar trend was observed for the TNF- α level [28]. Our data confirm that elevated levels of IL-6 and TNF- α are associated with an unfavorable prognosis.

Moreover, increased NLR and neutrophils counts are predictors of poor prognosis and severity of disease [29, 30] as well as elevated levels of CRP [31, 32]. Our results confirm these observations as shown by the higher levels of these laboratory indexes in the non-survivors group.

Recent studies have investigated the role of hepcidin as predictor of disease severity and mortality in COVID-19 patients [5, 10, 33]. In our work, all patients admitted to the ICU because of their severe pneumonia, showed elevated levels of hepcidin and these levels were even higher in those patients who did not survive and required an invasive mechanical ventilation.

Finally, ROC curve analyses showed that LDH and IL-6 have the best sensitivity and specificity, respectively. Nonetheless, hepcidin showed a sensitivity of 74% and a specificity of 76%, at a cut-off value of >127 ng/ml, suggesting that hepcidin measurement is a useful biomarker for predicting the severity and the outcome of COVID-19 in ICU patients. Furthermore, hepcidin could be used to define an algorithm along with other recent novel inflammatory biomarkers such as serum amyloid A protein (SAA) and mid-regional proadrenomedullin (MR-proADM) that have been recently evaluated for predicting mortality in COVID-19 patients [34, 35]. Higher levels of SAA were found in patients who died compared to the survivors [34]. Similarly, patients with a level of MR-proADM higher than 1105 nmol/L had a three-fold higher risk of mortality [35].

Lastly, although, they remain important indicators of disease severity [36], our analysis did not reveal statistically significant differences in the levels of fibrinogen, AST, ferritin, leucocytes and lymphocytes between the survivors and non-survivors groups.

A limitation of the study is the small sample size that might reduce the power of the results. However, this investigation confirms the usefulness of some biomarkers in predicting the severity and mortality of COVID-19 and brings important information about the utility of hepcidin measurement in COVID-19 patients admitted to ICU. All patients with an elevated hepcidin level had an unfavorable outcome.

Author Contributions: Conceptualization, M.C., E.C. and M.M.; methodology, M.N.; validation, M.N.; formal analysis, M.P.; investigation, C.M.P., F.L., A.G., T.C., L.R.; resources, E.C.; data curation, M.C.; writing—original draft preparation, M.C.; writing—review and editing, M.C., M.M.,

- M.N.; supervision, S.B., P.V. All authors have read and agreed to the published version of the manuscript." 239
240
- Funding:** This research was funded by GEFACOV2.0 research program coordinated by the Tor Vergata University of Rome and also supported by the contribution of "Fondazione Terzo Pilastro Internazionale", President Prof. Emmanuele Francesco Maria Emanuele. 241
242
243
- Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Policlinico Tor Vergata (protocol code 42.20/2020, 15 April 2020). 244
245
246
- Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study. 247
248
- Data Availability Statement:** Data are reported within the article. 249
- Conflicts of Interest:** The authors declare no conflict of interest. 250

References 251

1. Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. **2020**, *579*, 270–273. 252
253
2. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed [October 19, 2021]. 254
255
3. Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. **2020**, *323*, 1061. 256
257
4. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. **2020**, *395*, 497–506. 258
259
5. Nai, A.; Lorè, N.I.; Pagani, A.; De Lorenzo, R.; Di Modica, S.; Saliu, F.; Cirillo, D.M.; Rovere-Querini, P.; Manfredi, A. A.; Silvestri L. Hepcidin levels predict Covid-19 severity and mortality in a cohort of hospitalized Italian patients. *Am. J. Hematol.* **2021**, *96*, E32-E35. 260
261
262
6. Nemeth, E.; Ganz, T. The role of hepcidin in iron metabolism. *Acta. Haematol.* **2009**, *122*, 78–86. 263
7. Nemeth, E.; Ganz, T. Hepcidin-Ferroportin interaction controls systemic iron homeostasis. *Int. J. Mol. Sci.* **2021**, *22*, 6493. 264
8. Jiao, Y.; Yong, C.; Zhang, R.; Wang, D. Hepcidin alleviates LPS-induced ARDS by regulating the ferritin-mediated suppression of ferroptosis. *Shock*. **2022**, *57*(6), 274–281. 265
266
9. Ganz, T. Macrophages and systemic iron homeostasis. *J. Innate. Immun.* **2012**, *4*, 446–453. 267
10. Zhou, C.; Chen, Y.; Ji, Y.; He, X.; Xue, D. Increased serum levels of hepcidin and ferritin are associated with severity of COVID-19. *Med. Sci. Monit.* **2020**, *26*, e926178. 268
269
11. Zhao, K.; Huang, J.; Dai, D.; Feng, Y.; Liu, L.; and Nie, S. Serum iron level as a potential predictor of Coronavirus Disease 2019 severity and mortality: a retrospective study. *Open. Forum. Infect. Dis.* **2020**, *7*, 1–8. 270
271
12. Shah, A.; Frost, J.N.; Aaron, L.; Donovan, K.; Drakesmith, H.; & Collaborators. Systemic hypoferrremia and severity of hypoxemic respiratory failure in COVID-19. *Critical. Care*. **2020**, *24*, 320. 272
273
13. Ciotti, M.; Ciccozzi, M.; Pieri, M.; and Bernardini, S. The COVID-19 pandemic: viral variants and vaccine efficacy. *Crit. Rev. Clin. Lab. Sci.* **2022**, *59*, 66–75. 274
275
14. Gupta, A.; Madhavan, M.V.; Sehgal, K.; Nair, N.; Mahajan, S.; Sehrawat, T.S.; Bikdeli, B.; Ahluwalia, N.; Ausiello, J. C.; Wan, E.Y. Extrapulmonary manifestations of COVID-19. *Nature. Med.* **2020**, *26*, 1017–1032. 276
277
15. Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, J.J.; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. **2020**, *395*, 1033–1034. 278
279
16. Rostami, M.; Mansouritorghabeh, H. D-dimer level in COVID-19 infection: a systematic review. *Expert. Rev. Hematol.* **2020**, *13*, 1265–1275. 280
281
17. Nugroho, J.; Wardhana, A.; Maghfirah, I.; Mulia, E. P. B.; Rachmi, D. A.; Ayun, M. Q.; Septianda, I. Relationship of D-dimer with severity and mortality in SARS-CoV-2 patients: a meta-analysis. *Int. J. Lab. Hematol.* **2021**, *43*, 110–115. 282
283
18. Bansal, A.; Singh, A.D.; Jain, V.; Aggarwal, M.; Gupta, S.; Padappayil, R. P.; Nadeem, M.; Joshi, S.; Mian, A.; Greathouse, T.; et al. The association of D-dimers with mortality, intensive care unit admission or acute respiratory distress syndrome in patients hospitalized with coronavirus disease 2019 (COVID-19): A systematic review and metaanalysis. *Heart. Lung*. **2021**, *50*, 9–12. 284
285
286
287
19. Henry, B. M.; Aggarwal, G.; Wong, J.; Benoit, S.; Vikse, J.; Plebani, M.; and Lippi, G. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. *Am. J. Emerg. Med.* **2020**, *38*, 1722–1726. 288
289
20. Szarpak, L.; Ruetzler, K.; Safiejko, K.; Hampel, M.; Pruc, M.; Kanczuga - Koda, L.; Filipiak, K. J.; and Jaguszewski, M. J. Lactate dehydrogenase levels as a COVID-19 severity marker. *Am. J. Emerg. Med.* **2021**, *45*, 638–639. 290
291
21. Huang, Y.; Guo, L.; Chen, J.; Wu, M.; Zhang, C.; Liu, Z.; Li, J.; Li, K.; Xiong, Z.; Wu, Q.; et al. Serum lactate dehydrogenase level as a prognostic factor for COVID-19: a retrospective study based on a large sample size. *Front. Med.* **2022**, *8*, 671667. 292
293

22. Bao, J.; Li, C.; Zhang, K.; Kang, H.; Chen, W.; Gu B. Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19. *Clin. Chim. Acta.* **2020**, *509*,180–194. 294
295
23. Gu, Y.; Wang, D.; Chen, C.; Lu, W.; Liu, H.; Lv, T.; Song, Y.; Zhang, F. PaO₂/FiO₂ and IL-6 are risk factors of mortality for intensive care COVID-19 patients. *Sci. Rep.* **2021**,*11*, 1–8. 296
297
24. Sun, H.; Guo, P.; Zhang, L.; Wang F. Serum Interleukin-6 concentrations and the severity of COVID-19 pneumonia: a retrospective study at a single center in Bengbu City, Anhui Province, China, in January and February 2020. *Med. Sci. Monit.* **2020**, *26*, e926941. 298
299
300
25. Chen, G.; Wu, D.; Guo, W.; Cao, Y.; Huang, D.; Wang H.; Wang, T.; Zhang, X., Chen, H.; Yu, H.; et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J. Clin. Investig.* **2020**, *130*, 2620–2629. 301
302
26. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* **2020**, *395*, 497–506. 303
304
27. Halim, C.; Mirza, A. F.; and Sari, M.I. The Association between TNF- α , IL-6, and Vitamin D Levels and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis. *Pathogens.* **2022**, *11*, 195. 305
306
28. Del Valle, D. M.; Kim-Schulze, S.; Huang, H.H.; Beckmann, N.D.; Nirenberg, S.; Wang, B.; Lavin, Y.; Swartz, T.H.; Madduri, D.; et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med.* **2020**, *26*, 1636–1643. 307
308
29. Yang, A.P.; Liu, J.P.; Tao, W.Q.; Li, H.M. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. *Int. Immunopharmacol* **2020**, *84*, 106504. 309
310
30. Reusch, N.; De Domenico, E.; Bonaguro, L.; Schulte-Schrepping, J.; Baßler, K.; Schultze, J.L.; and Aschenbrenner, A.C. Neutrophils in COVID-19. *Front. Immunol.* **2021**, *12*, 652470. 311
312
31. Huang, I.; Pranata, R.; Lim, M. A.; Oehadian, A.; and Alisjahbana, B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. *Ther. Adv. Respir. Dis.* **2020**, *14*, 1–14. 313
314
32. Ochoa, N. E. L.; Rodríguez, G.; Reyes, I. D.; Rivas, K. M. R.; Ramírez, C.; Duron, R. M. Differences in inflammatory markers between coronavirus disease 2019 and sepsis in hospitalised patients. *Clin. Epidemiol. Glob. Health.* **2022**, *15*, 101059. 315
316
33. Hegelund, M. H.; Glenthøj, A.; Rysør, C. K.; Ritz, C.; Dungu, A. M.; Sejdic, A.; Knudsen List, K. C.; Krogh-Madsen, R.; Lindegaard, B.; Anders, J.; et al. Biomarkers for iron metabolism among patients hospitalized with community-acquired pneumonia caused by infection with SARS-CoV-2, bacteria, and influenza. *APMIS.* **2022**, DOI 10.1111/apm.13259 317
318
319
34. Pieri, M.; Ciotti, M.; Nuccetelli, M.; Perrone, M.A.; Calio, M.T.; Lia, M.S.; Minieri, M.; Bernardini, S. Serum Amyloid A Protein as a useful biomarker to predict COVID-19 patients severity and prognosis. *Int. Pharmacol.* **2021**, 107512. 320
321
35. Minieri, M.; Di Lecce, V.N.; Lia, M.S.; Maurici, M.; Leonardis, F.; Longo, S.; Colangeli, L.; Paganelli, C.; Levantesi, S.; Terrinoni, A.; et al. Predictive value of MR-proADM in the risk stratification and in the adequate care setting of COVID-19 patients assessed at the triage of the Emergency Department. *Diagnostics* **2022**, *12*, 1971. 322
323
324
36. Ciotti, M.; Ciccozzi, M.; Terrinoni, A.; Jiang, W-C. Wang, C.B., Bernardini, S. The COVID-19 pandemic. *Crit. Rev. Lab. Sci.* **2020**, *57*, 365–388. 325
326
327